Literature DB >> 35188328

LMOD2-related dilated cardiomyopathy presenting in late infancy.

Erica Lay1, Mahshid S Azamian1, Susan W Denfield2, William Dreyer2, Joseph A Spinner2, Debra Kearney3, Lilei Zhang1, Kim C Worley1, Weimin Bi1,4, Seema R Lalani1.   

Abstract

Leiomodin-2 (LMOD2) is an important regulator of the thin filament length, known to promote elongation of actin through polymerization at pointed ends. Mice with Lmod2 deficiency die around 3 weeks of age due to severe dilated cardiomyopathy (DCM), resulting from decreased heart contractility due to shorter thin filaments. To date, there have been three infants from two families reported with biallelic variants in LMOD2, presenting with perinatal onset DCM. Here, we describe a third family with a child harboring a previously described homozygous frameshift variant, c.1243_1244delCT (p.L415Vfs*108) with DCM, presenting later in infancy at 9 months of age. Family history was relevant for a sibling who died suddenly at 1 year of age after being diagnosed with cardiomegaly. LMOD2-related cardiomyopathy is a rare form of inherited cardiomyopathy resulting from thin filament length dysregulation and should be considered in genetic evaluation of newborns and infants with suspected autosomal recessive inheritance or sporadic early onset cardiomyopathy.
© 2022 Wiley Periodicals LLC.

Entities:  

Keywords:  LMOD2; autosomal recessive disease; dilated cardiomyopathy; loss of function variant; short thin filament length

Mesh:

Substances:

Year:  2022        PMID: 35188328      PMCID: PMC9117498          DOI: 10.1002/ajmg.a.62699

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.578


  16 in total

Review 1.  New-onset heart failure in children in the absence of structural congenital heart disease.

Authors:  Steven A Webber
Journal:  Circulation       Date:  2008-01-01       Impact factor: 29.690

2.  Incidence, causes, and outcomes of dilated cardiomyopathy in children.

Authors:  Jeffrey A Towbin; April M Lowe; Steven D Colan; Lynn A Sleeper; E John Orav; Sarah Clunie; Jane Messere; Gerald F Cox; Paul R Lurie; Daphne Hsu; Charles Canter; James D Wilkinson; Steven E Lipshultz
Journal:  JAMA       Date:  2006-10-18       Impact factor: 56.272

3.  Leiomodin-2 is an antagonist of tropomodulin-1 at the pointed end of the thin filaments in cardiac muscle.

Authors:  Takehiro Tsukada; Christopher T Pappas; Natalia Moroz; Parker B Antin; Alla S Kostyukova; Carol C Gregorio
Journal:  J Cell Sci       Date:  2010-08-24       Impact factor: 5.285

4.  Molecular findings among patients referred for clinical whole-exome sequencing.

Authors:  Yaping Yang; Donna M Muzny; Fan Xia; Zhiyv Niu; Richard Person; Yan Ding; Patricia Ward; Alicia Braxton; Min Wang; Christian Buhay; Narayanan Veeraraghavan; Alicia Hawes; Theodore Chiang; Magalie Leduc; Joke Beuten; Jing Zhang; Weimin He; Jennifer Scull; Alecia Willis; Megan Landsverk; William J Craigen; Mir Reza Bekheirnia; Asbjorg Stray-Pedersen; Pengfei Liu; Shu Wen; Wendy Alcaraz; Hong Cui; Magdalena Walkiewicz; Jeffrey Reid; Matthew Bainbridge; Ankita Patel; Eric Boerwinkle; Arthur L Beaudet; James R Lupski; Sharon E Plon; Richard A Gibbs; Christine M Eng
Journal:  JAMA       Date:  2014-11-12       Impact factor: 56.272

5.  Leiomodin is an actin filament nucleator in muscle cells.

Authors:  David Chereau; Malgorzata Boczkowska; Aneta Skwarek-Maruszewska; Ikuko Fujiwara; David B Hayes; Grzegorz Rebowski; Pekka Lappalainen; Thomas D Pollard; Roberto Dominguez
Journal:  Science       Date:  2008-04-11       Impact factor: 47.728

6.  Cardiac-specific knockout of Lmod2 results in a severe reduction in myofilament force production and rapid cardiac failure.

Authors:  Christopher T Pappas; Gerrie P Farman; Rachel M Mayfield; John P Konhilas; Carol C Gregorio
Journal:  J Mol Cell Cardiol       Date:  2018-08-11       Impact factor: 5.000

Review 7.  Pediatric cardiomyopathies: causes, epidemiology, clinical course, preventive strategies and therapies.

Authors:  Steven E Lipshultz; Thomas R Cochran; David A Briston; Stefanie R Brown; Peter J Sambatakos; Tracie L Miller; Adriana A Carrillo; Liat Corcia; Janine E Sanchez; Melissa B Diamond; Michael Freundlich; Danielle Harake; Tamara Gayle; William G Harmon; Paolo G Rusconi; Satinder K Sandhu; James D Wilkinson
Journal:  Future Cardiol       Date:  2013-11

8.  Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Authors:  Sue Richards; Nazneen Aziz; Sherri Bale; David Bick; Soma Das; Julie Gastier-Foster; Wayne W Grody; Madhuri Hegde; Elaine Lyon; Elaine Spector; Karl Voelkerding; Heidi L Rehm
Journal:  Genet Med       Date:  2015-03-05       Impact factor: 8.822

9.  Disruption of cardiac thin filament assembly arising from a mutation in LMOD2: A novel mechanism of neonatal dilated cardiomyopathy.

Authors:  Rebecca C Ahrens-Nicklas; Christopher T Pappas; Gerrie P Farman; Rachel M Mayfield; Tania M Larrinaga; Livija Medne; Alyssa Ritter; Ian D Krantz; Chaya Murali; Kimberly Y Lin; Justin H Berger; Sabrina W Yum; Chrystalle Katte Carreon; Carol C Gregorio
Journal:  Sci Adv       Date:  2019-09-04       Impact factor: 14.136

10.  Prospective Evaluation of the Utility of Whole Exome Sequencing in Dilated Cardiomyopathy.

Authors:  Jay Ramchand; Mathew Wallis; Ivan Macciocca; Elly Lynch; Omar Farouque; Melissa Martyn; Dean Phelan; Belinda Chong; Siobhan Lockwood; Robert Weintraub; Tina Thompson; Alison Trainer; Dominica Zentner; Jitendra Vohra; Michael Chetrit; David L Hare; Paul James
Journal:  J Am Heart Assoc       Date:  2020-01-14       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.